# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: David Hume (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN012-SYN
- Date: 2026-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Fiona Gallacher, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Review after completing adjuvant chemotherapy; start of surveillance. **S**

## History of present illness

Mr. Hume returns two weeks after the last capecitabine dose of his fourth and final CAPOX cycle. The DPYD genotype before cycle 1 showed no decreased-function variant, and he received all four cycles on schedule at full dose. In cycle 2 he had three days of loose stools, controlled with loperamide. His September cold resolved without complications. Cold-triggered tingling after each oxaliplatin dose has left mild numbness of the fingertips and toe tips that does not interfere with buttoning, writing, or walking, and is not painful. He has no bowel bleeding or change in habit, no abdominal pain, cough, or bone pain. He walks 30 minutes a day and writes every morning. He feels well and asks what the follow-up will be. **S**

| Element | Detail |
|---|---|
| Treatment | Four cycles of CAPOX completed at full dose |
| Toxicity | Grade 1 diarrhea in cycle 2; grade 1 sensory neuropathy; no hand-foot syndrome |
| Recurrence symptoms | None: no bleeding, change in bowel habit, pain, cough, or weight loss |
| Function | Walking 30 minutes a day; writing daily |
| Weight | 81.0 kg, down 1.5 kg since the postoperative visit |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild tiredness in the afternoons; no fever or night sweats |
| Gastrointestinal | Negative | Formed stools once or twice a day; no blood or pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain |
| Neurological | Positive | Numb fingertips and toe tips, not painful; no weakness or imbalance |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

6 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/74 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 81 kg; BMI 25.6 kg/m². All vital signs are synthetic.

CEA: 1.8 ng/mL; Hemoglobin: 12.8 g/dL (low); MCV: 89 fL; White cell count: 5.2 10*3/uL; Absolute neutrophil count: 2.9 10*3/uL; Platelets: 128 10*3/uL (low); Creatinine: 0.92 mg/dL; eGFR: 93 mL/min/1.73 m²; ALT: 31 U/L; Total bilirubin: 0.7 mg/dL; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.6 g/dL (low) at baseline, 12.8 g/dL (low) at this visit **S**
- MCV: 74 fL (low) at baseline, 89 fL at this visit **S**
- White cell count: 7.4 10*3/uL at baseline, 5.2 10*3/uL at this visit **S**
- Platelets: 438 10*3/uL (high) at baseline, 128 10*3/uL (low) at this visit **S**
- Creatinine: 0.94 mg/dL at baseline, 0.92 mg/dL at this visit **S**
- eGFR: 91 mL/min/1.73 m² at baseline, 93 mL/min/1.73 m² at this visit **S**
- ALT: 22 U/L at baseline, 31 U/L at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Abdomen | Scars healed; soft; no mass or liver enlargement |
| Lymph nodes | No supraclavicular or inguinal nodes |
| Neurological | Reduced light touch at the fingertips and toe tips; vibration slightly reduced at the toes; proprioception, strength, ankle reflexes, and Romberg normal |
| Skin | Palms and soles normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Resected stage IIIB sigmoid adenocarcinoma, adjuvant therapy complete, no evidence of disease** (C18.7). CEA 1.8 ng/mL, and no symptoms or signs of recurrence. Surveillance begins on the CMID colorectal cancer schedule. **S**
   - Written survivorship care plan given today: treatment summary, surveillance schedule, late effects, and whom to call.
   - History, examination, and CEA every three months for two years, then every six months to five years.
   - CT of the chest, abdomen, and pelvis in December, six months after surgery, then every 6 to 12 months for five years.
   - Colonoscopy one year after resection, in June.
2. **Oxaliplatin-induced sensory neuropathy, grade 1** (G62.0). Non-painful and not limiting function. It often improves over months, though some can persist. **S**
   - Check at every visit.
   - Duloxetine only if it becomes painful.
   - Protect the feet; check them daily.
3. **Anemia, now mild and related to chemotherapy** (D50.0). Hemoglobin 12.8 g/dL and platelets 128, expected after oxaliplatin; iron was replete before chemotherapy. **S**
   - Repeat blood count with the January CEA.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | CEA | Every 3 to 6 months for 2 years, then every 6 months to 5 years | Completed today | 1.8 ng/mL, normal |
| Laboratory | Blood count after chemotherapy | At the end of treatment | Completed today | Hemoglobin 12.8 g/dL, MCV 89 fL, white cells 5.2, neutrophils 2.9, platelets 128 |
| Laboratory | Kidney and liver function | At the end of treatment | Completed today | Creatinine 0.92 mg/dL, eGFR 93; ALT 31 U/L, bilirubin 0.7 mg/dL |
| Examination | History and physical examination | Every 3 to 6 months for 2 years | Completed today | No evidence of recurrence |
| Examination | Peripheral neuropathy (CIPN) | Every visit during and after oxaliplatin | Completed today | Grade 1 sensory neuropathy, not painful |
| Survey | Distress and depression screen (PHQ-2) | At each follow-up visit | Completed today | PHQ-2 score 0 |
| Survey | Fatigue | Every visit | Completed today | Mild afternoon tiredness; activity advised |
| Imaging | CT of the chest, abdomen, and pelvis | Every 6 to 12 months for 5 years | Due | In December, six months after surgery |
| Examination | Surveillance colonoscopy | One year after resection, then at three years, then every five years | Due | In June; the preoperative colonoscopy was complete |
| Medication safety | Duloxetine for painful neuropathy | If neuropathy is painful | Not indicated | Neuropathy is not painful |
| Referral | Genetic counseling | Once | Due | Appointment next month, after chemotherapy as he asked |
| Self-management | Survivorship care plan and lifestyle counseling | Within one year of treatment completion; lifestyle every visit | Completed today | Written plan given; 150 minutes of activity a week, a diet low in red and processed meat, alcohol at or below one drink a day |

## Goal progress

- Complete diagnosis, staging, and curative resection within six weeks of presentation. Outcome by 2026-07-13: Colonoscopy in eight days, staging complete in three and a half weeks, colectomy at five weeks. **S**
- Replete iron stores before surgery and recover hemoglobin by the postoperative review. Outcome by 2026-07-13: Ferritin 186 ng/mL and hemoglobin 12.4 g/dL four weeks after surgery, up from 9 ng/mL and 10.6 g/dL. **S**
- Complete three months of adjuvant CAPOX with neuropathy no worse than grade 1. Outcome by 2026-10-19: Four cycles completed on schedule; grade 1 sensory neuropathy. **S**
- Start survivorship surveillance with a written survivorship care plan. Outcome by 2026-10-19: Survivorship care plan given; CEA 1.8 ng/mL; CT and colonoscopy dates set. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025), National Comprehensive Cancer Network
- The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer (2021), American Society of Colon and Rectal Surgeons
- American Cancer Society Colorectal Cancer Survivorship Care Guidelines (2015), American Cancer Society (endorsed by ASCO)
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026), Aether Forge

## Follow-up

- Adult preventive visit later this month. CT in December. Surveillance visit with CEA and blood count in January. **S**
- Next scheduled visit 2026-10-28: adult preventive visit. **S**
